Edwards Lifesciences Corporation (NYSE:EW) Q1 2025 Earnings Call Transcript

Edwards Lifesciences Corporation (NYSE:EW) Q1 2025 Earnings Call Transcript April 23, 2025

Edwards Lifesciences Corporation beats earnings expectations. Reported EPS is $0.64, expectations were $0.596.

Operator: Greetings, and welcome to the Edwards Lifesciences First Quarter 2025 Results. At this time, all participants are in a listen-only mode. A question and answer session will follow the formal presentation. If you require operator assistance during the conference, as a reminder, this conference is being recorded. It is now my pleasure to introduce you to your host, Mark Wilterding, Senior Vice President Global Finance. Thank you, Mark. You may begin.

Mark Wilterding: Thanks, Alicia, and thank you everyone for joining us this afternoon. Joining me on today’s call is our CEO, Bernard Zovighian, and our CFO, Scott Ullem. Also joining us for the Q&A portion of the call will be Larry Wood, our Global Head Global Group President of TAVR and Surgical, Daveen Chopra, our Global Leader of TMTT, and Wayne Markowitz, our Global Leader of Surgical. Just after the close of regular trading, Edwards Lifesciences released first quarter 2025 financial results. During today’s call, management will discuss those results included in the press release and accompanying financial schedules and then use the remainder of time for Q&A. Please note that management will be making forward-looking statements that are based on estimates, assumptions, and projections.

These statements speak only as of the date on which they were made, and Edwards does not undertake any obligation to update them after today. Additionally, the statements involve risks and uncertainties that could cause actual results to differ materially. Information concerning factors that could cause these differences can be found in today’s press release and Edwards’ other SEC filings, all of which are available on the company’s website at edwards.com. Edwards’ guidance reflects its current estimates of the impact from tariffs that are in effect or have been announced as of the time of this press release and assume such tariffs remain in place for the remainder of 2025. Any modification to such tariffs or new tariffs could have a material impact on the company’s future financial results and guidance.

Unless otherwise noted, our commentary on sales growth refers to constant currency sales growth, which is defined in the quarterly results press release issued earlier today. Reconciliations between GAAP and non-GAAP numbers mentioned during this call are also included in today’s press release. Quarterly and full-year growth rates refer to continuing operations and do not include discontinued operations. With that, I’d like to turn the call over to Bernard for his comments.

Bernard Zovighian: Thank you, Mark. Welcome everyone, and I am pleased that confidence total company sales grew 8% to $1.041 billion in the first quarter, reflecting the benefits of our broad and differentiated portfolio of therapies to treat patients with structural heart disease. The many milestones achieved in Q1 are the result of our focused strategy and our decades of unwavering dedication to driving breakthrough innovation in pioneering and leading categories. Collectively, these milestones mark the significant progress we have made to unlock this large and growing opportunity to transform care for millions of structural heart patients around the world. I’d like to thank our 16,000 global employees for their many contributions to advancing patient care.

TAVR growth in the quarter was better than expected, as clinicians continue to adopt our best-in-class SAPN technology. Looking ahead to the rest of the year, we continue to believe that the results of an early TAVR trial represent a multiyear growth opportunity that will begin with the expected indication approval in the second quarter and expand with the evolution of policy and guideline changes in the US and globally. And in late 2026, we look forward to the presentation of the results of a groundbreaking progress trial, which has the potential to further expand the therapy to many new patients with moderate AS. I am proud of our commitment to TAVR innovation and high-quality science that is increasing the access to treatment options for all AS patients.

We continue to be pleased with TMTT’s strong momentum reflecting our portfolio of differentiated repair and replacement technologies, and we are raising our 2025 TMTT sales guidance range to $530 to $550 million. As a reminder, our successful TMTT strategy positions us to become the first to develop and launch a transcatheter tricuspid valve with Evoque in 2024. Today, I am also very proud of the recent approval of our SAPIEN M3 in Europe, the world’s first transcatheter mitral valve replacement system, which will benefit many patients with mitral regurgitation who have limited treatment options. This breakthrough technology demonstrates our team’s long-term and steadfast commitment to solving large unmet patient needs. And with Evoque, M3, and Pascal, we are uniquely positioned to meet the broad and diverse needs of patients with tricuspid and mitral valve diseases.

In surgical, our category-leading business continues to benefit from increasing adoption of our premium Resilia portfolio, Inspiris, Mitris, and Connect. Edwards continues to invest in surgical innovation and evidence as we expand access to our therapies globally. Last week, at the Heart Valve Society meeting, ATF data were presented, demonstrating the excellent durability of the company’s novel Resilia tissue, which is used in a wide range of Edwards surgical platforms as well as SAPIEN 3 Ultra Resilia. The results represent the longest follow-up study on the durability of valves, which highlights our dedication to pioneering unique innovation. With patients of all ages living longer and seeking higher quality of life, the importance of lifetime management has never been greater.

We also continue to make steady progress advancing our portfolio of emerging opportunities, which we discussed at our investor conference in December. Our team continues to build capabilities to reach the millions of patients around the world who suffer from structural heart failure. And in aortic regurgitation, we are enrolling patients in JOURNEY, the pivotal trial for the Edwards JVAS AR system. Turning to our 2025 financial outlook, we are confident in our full-year total company sales growth guidance of 8% to 10%, and we have plans in place to offset the estimated impact of currently announced tariffs and the estimated dilution from the Yenovale acquisition, which we are planning to close midyear. As a result of our plans, we are in a position to deliver on our original EPS guidance of $2.40 to $2.50.

Our priorities continue to be serving the patients who count on us and maintaining the highest level of service and support to our physician partners around the world. Looking ahead to 2026 and beyond, Edwards is positioned to transform care for the many structural heart patients in need. We are confident that our strategic focus, unique innovation strategy, and exceptional work of our employees around the world will deliver significant value to patients, the healthcare ecosystem, and shareholders. Now I will provide some additional detail by product group for Q1. In TAVR, our first quarter global sales of $1.05 billion increased 5.4% over the prior year or 6.5% when adjusted for billing days, which was a little higher than expected. Growth was comparable in the US and OUS, and while strong competitive position and pricing remain stable globally, with some regional variability.

I am proud of our team’s commitment to leading with science supported by a decade of clinical research that set the standard for quality evidence and physician decision-making. This significant body of high-quality science from rigorous FDA trials underscores the excellent clinical outcomes delivered by Edwards’ premium SAPIEN technology. Last month, at the American College of Cardiology Conference, new clinical data from the early TAVR trials studying patients with asymptomatic severe AS were released. The data highlighted that delaying aortic valve replacement in this patient population was associated with worse outcomes. Additionally, a new study using cardiac biomarkers revealed the rapid and unpredictable progression of the disease. Both studies underscore the need for urgent referrals for treatment evaluation for severe AS patients, regardless of symptoms.

Also, at ACC, new groundbreaking data from the DETECT AS study were presented. DETECT AS is the first randomized trial evaluating the impact of physician notification or echo alert for their patients with severe AS that meet treatment guidelines. The study found that these echo alerts increased both treatment and survival rates for patients with severe AS. In the US, our leading SAPIEN 3 Ultra Resilia platform continues to demonstrate strong performance. We are advancing initiatives to help hospitals treat structural heart patients efficiently and manage increasing procedure volumes. We are encouraged by hospitals that have demonstrated the ability to scale to accommodate positive growth. We are encouraged by discussions with key clinicians on the long-term impact of early TAVR data to streamline patient care.

In addition, we expect asymptomatic indication approval in the second quarter. Outside of the US, we continue to focus on the value of our differentiated technology and increasing therapy adoption, especially in areas where TAVR remains underutilized and many patients go without care. In the first quarter, sales growth was supported by the continued expansion of SAPIEN 3 Ultra Resilia in Europe. SAPIEN 3 Ultra Resilia continues to deliver exceptional clinical outcomes and reinforce the differentiation of this best-in-class platform. In Japan, we continue to face a weaker procedure growth environment and competitive pressure. We remain dedicated to addressing the significant undertreatment of AS among the substantial elderly population in Japan.

In summary for TAVR, we are maintaining our full-year sales growth guidance of 5% to 7%. Long-term, we are enthusiastic about the durable mid to high single-digit growth opportunity in TAVR, supported by the upcoming early TAVR indication approval and guideline and policy changes, and the potential to serve patients with moderate AS. Turning to TMTT, our unique and increasingly differentiated portfolio drove another quarter of impressive growth, with a meaningful contribution to overall company performance. We are pleased with first-quarter sales of $150 million, representing growth of about 60%, and led by increased adoption and balanced contribution from Pascal and Evoque in the US, Europe, and globally. We continue to see strong share adoption and expansion across both mitral and tricuspid.

Globally, mitral tier procedures continue to grow double digits, and the developing tricuspid opportunity is growing even faster across both repair and replacement. Pascal continues to demonstrate its value for patient care. Its differentiated features are driving distinguished clinical outcomes, and adoption is increasing at both new and existing sites around the world. The Evoque commercial launch is progressing well in the US and Europe, with continuing excellent patient outcomes. At the end of March, we were pleased to see the finalization of the NCD for transcatheter tricuspid valve replacement for patients suffering from tricuspid disease. With the new NCD, Evoque is now covered for all Medicare beneficiaries who meet the criteria outlined in the final coverage policy, expanding patient access to this important therapy.

We are pleased with the recent approval of the SAPIEN M3 mitral valve replacement system in Europe. This revolutionary transcatheter-based therapy is built on the proven SAPIEN platform, which has been used in more than 8,000 procedures in the mitral position. We continue to expect that results from the ENCIRCLE pivotal trial studying M3 will be presented at the TCT conference in October of 2025. In addition, as part of our deep commitment to advancing science for patients with structural heart disease, a European post-market follow-up study is planned to continue evaluation of SAPIEN M3, following patients out to five years. As previously shared, we expect US approval of SAPIEN M3 to follow in 2026. The launch plan for SAPIEN M3 in Europe is focused on creating a new category as we have done many times before and achieving excellent patient outcomes.

With our decades of experience, we are uniquely positioned to bring SAPIEN M3 to the many patients in need across Europe. We will work with all stakeholders to ensure patient access to this novel therapy, providing physician training and working with policymakers to establish proper therapy coverage. Edwards is the only company that offers a transcatheter portfolio that includes both replacement and repair treatment options for both the mitral and tricuspid valve, meeting the complex needs of underserved patients. We are committed to bringing this portfolio to patients in need around the world and expect meaningful impact from these advanced therapies in 2026 and beyond. In our surgical product group, first-quarter global sales of $251 million increased 3% over the prior year.

We continue to see positive procedure growth globally for the many patients best treated with Edwards’ premium portfolio, including Mitris, Inspiris, and Connect. We continue to generate high-quality evidence on our Resilia Tissue technology. As shown in the eight-year data presented at the recent Heart Valve Society meeting, Resilia tissue valves had significantly improved freedom from structural valve deterioration and freedom from reoperation compared to non-Resilia valves. Also in the quarter, our surgical team made progress advancing important innovation around the world. Mitris launched in China with positive surgeon feedback, and we anticipate receiving CE Mark approval for the Connect aortic valve conduit in Europe before year-end. And now Scott will cover a detail of the company financial performance.

Scott Ullem: Great. Thanks a lot, Bernard. As Bernard mentioned, we are pleased with our first-quarter total company sales performance and progress on our strategic milestones, which gives us confidence in our full-year outlook. We are raising our original sales guidance range for TMTT to $530 to $550 million, driven by more favorable foreign exchange and continued business momentum. Total company, TAVR, and surgical sales growth guidance ranges remain unchanged, but the company is increasing our original total company sales dollar guidance range by $100 million to account for recent movement in FX rates. Edwards now expects total company sales of $5.7 to $6.1 billion in 2025. So now I’ll cover additional details of our Q1 results starting with earnings per share.

We generated adjusted EPS of $0.64 in the quarter, with solid operating performance. Our GAAP EPS for the quarter was $0.62. A full reconciliation between our GAAP and non-GAAP measures, including adjusted EPS and other items, is included with today’s release. Moving on to other elements of the P&L. For the first quarter, our adjusted gross profit margin was 78.7%, compared to 78.5% in the same period last year. We are maintaining our full-year 78% to 79% gross margin guidance at this stage. However, we do expect some pressure from the weakening dollar, the impact of announced tariffs, and the expected close of the Yenovale acquisition. Selling, general, and administrative expenses in the quarter were $466 million or 33% of sales, which was better than our expectation for the quarter driven by lower sequential spending and deferral of certain strategic investments originally planned for Q1.

Research and development expense of $255 million in the first quarter was equivalent to 18% of sales, a reduction from 19.6% of sales in the previous quarter. This lower ratio of spending reflects the company’s prioritized investments in our structural heart portfolio in areas where we believe there are significant opportunities for breakthrough innovation and profitable growth. Adjusted operating profit margin in the first quarter of 29.1% was driven by better-than-expected sales and favorable mix, as well as some variable expenses delayed beyond Q1. We expect pressure on our operating margin as a result of the weakening dollar, the impact of announced tariffs, and the expected midyear close of the Yenovale acquisition. However, we are implementing plans to mitigate these anticipated costs, and we maintain our full-year operating margin guidance of 27% to 28% and our EPS guidance of $2.40 to $2.50.

We continue to expect our 2025 tax rate, excluding special items, to be between 15% and 18%. Foreign exchange rates decreased first-quarter reported sales growth by 170 basis points or $22 million compared to the prior year. FX rates positively impacted our first-quarter gross profit margin by 40 basis points compared to the prior year. Relative to our February guidance, FX rates had a nominal impact on first-quarter earnings per share. At current rates, we now estimate no impact from foreign exchange on reported sales in 2025 relative to 2024, versus our investor conference guidance of a $100 million reduction. As a reminder, our hedging strategy is designed to mitigate the impact of foreign currency fluctuation on the original EPS guidance we provided in December.

Turning to the balance sheet, we continue to maintain a strong and flexible balance sheet with approximately $3 billion in cash and cash equivalents as of the end of the quarter. During the first quarter, the company entered into an ASR agreement and repurchased stock through a pre-established plan totaling $300 million. Edwards has approximately $1 billion remaining under our share repurchase authorization. Average diluted shares outstanding during the quarter were 588 million. We continue to expect average diluted shares outstanding for 2025 to be between 585 to 595 million. So I’ll finish with one final guidance comment. For the second quarter, we’re projecting sales of $1.45 to $1.53 billion and adjusted earnings per share of $0.59 to $0.65.

And with that, I’ll pass it back to Bernard.

Bernard Zovighian: Hey. Thanks, Scott. Before I close you, like, this afternoon, I want to take a moment to acknowledge an important milestone for our company. It was 25 years ago this month that we rang the bell at the New York Stock Exchange and officially began our journey as Edwards Lifesciences. Since then, we have transformed care for millions of structural heart patients around the world, solving large and complex patient needs and pioneering therapeutic categories. And our future is bright. Our foundation remains strong, and we will continue to bring new innovation to the many structural heart patients in need around the world. With that, I’ll turn it back to Mark.

Mark Wilterding: Thank you very much, Bernard. We are ready to take your questions. As a reminder, please limit the number of questions plus one follow-up to allow for broad participation. If you have additional questions, please reenter the queue. And management will answer as many participants as possible during the remainder of the call. Alicia, I’ll turn it over to you.

Operator: Thank you. We’ll now be conducting the question and answer session. You may press star two if you would like to remove your question from the queue. One moment please while we poll for questions. Thank you. Our first question comes from the line of Larry Biegelsen with Wells Fargo. Please proceed.

Q&A Session

Larry Biegelsen: Good afternoon. Thanks for taking the question. Congrats on a good start to the year here. Scott, you can probably anticipate the first question. You’re maintaining the EPS guidance despite the tariffs and the Yenovale acquisition and maybe even currency. So, obviously, people would love to hear you parse out how much each of those impact 2025 and how much lower could the gross margin be relative to the guidance, and I had one follow-up.

Scott Ullem: Sure. So let’s go through the three elements, Larry. Thanks for the question. On FX, you know, our hedging program is designed to mute the impact of foreign exchange changes on our EPS. So the real impact is from tariffs and the Yenovale acquisition. You know, for tariffs, it’s probably about $0.05 to EPS based upon the tariffs that are already in place. And, you know, just a little color commentary on tariffs, we may not be as complex as some others because we operate just a handful of production facilities that are strategically located with our key business regions. And, you know, we also already have a lot of production in the US. And so think $0.05 associated with the 10% tariffs. Now that’s just for 2025. The tariff impact is higher than that, but as you know, they get capitalized into inventory and recognized in our P&L as finished goods are sold.

So the bigger impact is in 2026, but it’s premature to be offering any guidance or speculation about what tariffs could look like when we get out there. For Yenovale, we think the impact is probably in the range of $0.05 to $0.10. Now keep in mind, we don’t have current information. We haven’t closed the deal yet. But based upon our estimates and the preliminary plans we have for integration, that’s probably a good estimate.

Larry Biegelsen: That’s very helpful. And a follow-up for Daveen. On tricuspid. Congratulations on the NCD for Evoque. How do you see the NCD impacting the ramp of Evoque? Thanks for taking the questions.

Daveen Chopra: Thanks, Larry. Thanks so much for the question. Right? We can’t be more excited about Evoque as a new category for us. Right? It’s a great product. And the NCD, as you know, was effective now in March of 2025, and this is a transcatheter tricuspid valve replacement NCD. The NCD ensures that both the standard Medicare as well as the large Medicare Advantage patient groups have access to Evoque as outlined in the final coverage policy. This coverage policy was very much in line with our expectations. So it’s kind of built into our guidance this year. We love the components of this NCD, including, you know, within an FDA-approved indication under our heart team and in the context of a CED or coverage with evidence development to collect additional data on the therapy.

So overall, it is in line with our expectations of 2025 being full steam with activating new sites and continuing to treat more patients with Evoque who are getting excellent outcomes. And this is the start of a great multiyear kind of growth opportunity for treating more patients.

Operator: Thank you. Our next question comes from the line of David Roman with Goldman Sachs. Please proceed.

David Roman: Thank you. Good afternoon. I wanted just to start on the TAVR business. And maybe you could talk us through a little bit what you’re seeing on the ground as it relates to either referral patterns or physician engagement post the presentation early TAVR now that we’re kind of six months following TCT? And then maybe walk us through specifically what happens once you get the indication expansion approved and what the plan is to start to support market development effort and when we should see that show up in numbers, then I have a one follow-up.

Bernard Zovighian: Thanks, David. Yeah. That’s a great question. Well, first of all, I think the dataset was very, very strong that we presented at TCT. It does take physicians a little bit of time to work their way through the data and really the important nuances. We followed up those, the TCT with a very strong deep dive at ACC, and there were a few things that came out of that. One was the unpredictable nature of these patients that have asymptomatic aortic stenosis. I think one of the things that a lot of people have been utilizing and have been focused on is the use of biomarkers. And the thought being that biomarkers would be predictive would help physicians understand what asymptomatic patients they should refer and what patients they could safely wait on.

And I think the surprising data that came out at ACC said the biomarkers were actually not predictive. They did not predict which patients had more serious events versus which patients just had a progression to more mild symptoms. So I think it just really stresses that these patients need to get referred. They need to get worked up by the heart team. And we’ve continued to work with the clinical community and our physicians to make sure we amplify that message. But, of course, you know, all we can do right now is just educate people on the publications on the data. We can’t actually promote in any way, shape, or form treating patients who are truly asymptomatic because we don’t have the indication yet. We do expect that to come before midyear, so we’re on track for that.

And the minute we get the indication approval, we have, you know, a very detailed education plan. We can then begin reaching out to the referral base and doing all of the other things that we want to do to help amplify this message. But, you know, again, we expect the approval to happen in Q2.

David Roman: Got it. Thanks for the detail there. And then on the TMTT side, you kind of look twelve to twenty-four months forward, I believe you’ll have tricuspid repair and replacement, mitral repair and replacement available US and OUS. So can you maybe help us just think about market segmentation a little bit in that category? How should we think about mix between repair and replacement today and going forward? And whether this category is more of a sort of, quote, toolbox approach for physicians or you think it converts to a one size fits all, be it in mitral or tricuspid?

Bernard Zovighian: You know, thanks, David. You know, let me start, and then I will ask Daveen to add, you know, some additional details. You know, I want to start, you know, where we were, you know, a few years ago. You know, we knew that a tier technology and repair technology was not going to be sufficient to unlock and have a full potential of a mitral and tricuspid space. So it is why, you know, we went in with the toolbox. And, you know, we brought, you know, first, you know, Pascal, you know, highly differentiated. And you have seen, you know, the kind of impact, you know, we are having on patients with Pascal. But we know that, you know, many patients cannot be treated with tier. So, therefore, you know, we launched, we were the first to launch, you know, Evoque, which is going very well, and we see we are treating, you know, more patients than just, you know, tier patients, tricuspid patients with Evoque.

Here, we then free to, you know, it’s the beginning of a sad journey here. It is going to take us multiple years to train physicians, expand. So to give you a sense about segmentation, right now, it is a little bit early, but Daveen is very close to that. So maybe I ask Daveen to bring some color here.

Daveen Chopra: Yeah. As Bernard said, it’s hard to give the exact segmentation, but I’ll try to give you at least some thoughts we have. Today in Europe now, as Bernard said, we have now repair and replacement for each mitral and tricuspid. So we believe with the two technologies together, we can treat a larger group of patients. Clearly, on the mitral side again in Europe, M3 has just gotten approved. And for SAPIEN M3, it’ll be over time to really build out this category. To train physicians, to get appropriate payment, etcetera, over time. And for that, we see we remember that the M3 that this is a product that’s geared toward the tier and mitral surgery, unsuitable patients. So it’s for patients who don’t have TIR or surgery options.

So over time, we still believe TIR coming years will be the largest part, and then eventually over time, mitral replacement will continue to grow in its treatment of people offering that new option. In tricuspid in Europe, again, it’s a little different, sir, in the US than the US where tricuspid TIR has been around for many years. And now, the new category of Evoque has been recently created in Europe. Where we’re now adding more patients to the pool who are both tricuspid surgery and tricuspid TIR ineligible. So now we’re adding new patients who don’t have an option in producing these amazing results. So that’s how we see the European market progressing this couple of years. The US will have a little bit different dynamics, but you’ll still see that because TIR has been very well established in the mitral space, we see mitral replacement as an additive therapy bringing patients off the sideline and offering a solution that they didn’t have before.

In the tricuspid space, as you know, both repair and replacement entered the US market at similar times. So the clinical community right now is learning together about, here, which is the best repair patient and which is the best replacement patient. We’ve seen from experience in Europe so far that having a repair and a replacement solution is really important for treating the maximum number of patients. But the exact ratio we’re gonna figure that out together with clinicians in the coming years.

David Roman: Great. Thanks so much.

Operator: Thank you. Our next question comes from the line of Travis Steed with Bank of America. Please proceed.

Travis Steed: Hey. Congrats on the quarter. First question I wanted to ask on TAVR, capacity constraints and the potential for the TAVR NCD to loosen some of the requirements or potentially broaden some of the number of centers available to treat. That’s some of the ways that some of the capacity constraints can be eased over time.

Bernard Zovighian: Sure. Thanks for the question. Yeah. You know, we certainly feel if, you know, it’s the time to reopen the NCD. We think there’s a number of things that need to be updated. You know, the first is the NCD needs to specifically cover asymptomatic patients just to ensure national coverage is standardized for all the patients that need that therapy. I think the second thing is we know that adding hospitals that could offer this therapy would improve care and give more people access. And I think that’s, you know, another important element. In terms of more broadly on capacity, I think some of the acute capacity issues that we dealt with last year, I think we’re through the worst of that. We still see centers working actively to, you know, to add capabilities.

And, you know, we try to partner really closely with them. You know, we offer valve clinic coordinator training courses. So if that’s the constraint, you know, we can certainly help them train their staff. Some places, you know, it’s more about anesthesia, and so we can, you know, bring in experts to help them adopt conscious sedation. You know, if they’re just, you know, limited to, you know, two or three cases a day, we can bring in things like our benchmark program that can allow them to do more cases in the same time and in the same footprint. So we continue to work with them. I think, you know, the reality is we have a lot of new technology. We have a lot of new indications coming. I think hospitals realize that, and I think they are investing.

We’ve seen that. And they’ll continue to do so. But the reality is they need to keep doing that because, you know, the indications, you know, right now, it’s gonna be, you know, in the near term, asymptomatic, but we know we already have Evoque. We know we have M3 coming. And then, you know, we’re only, you know, a year and a half away from seeing the progress data, which could be another indication expansion. So I think the hospitals are more in tune with what the requirements are gonna be on a go-forward. I think it’s gonna be all those things coming together. I think it’s gonna be policy. I think it’s gonna be guidelines. I think it’s gonna be those investments that are gonna be the long-term solutions to capacity.

Travis Steed: Great. That’s helpful. And then I had a follow-up with a modeling question on Q2 TAVR. I think that’s right. It’s 5.8%. I’m just curious if there’s any color you wanna provide on how to model Q2 TAVR in the remainder of the year in the second half. And any days benefit to kind of call out over the course of the year or the remaining portion of the year.

Scott Ullem: 5.4% growth in the first quarter. And to the midpoint of our 5% to 7% growth rate guidance for the year, you know, it tells you we need something in the 6% range for each of Q2, 3, and 4. Obviously, there are gonna be some differences. We’ve got some changes coming during the course of the year, including they simply Travis is in that 6% range with some expected variability quarter to quarter.

Travis Steed: Great. Thanks a lot.

Operator: Our next question comes from the line of Robbie Marcus with JPMorgan. Please proceed.

Robbie Marcus: Oh, great. Good quarter. Thanks for taking the questions. Two for me. Scott, maybe just on the EPS offsets, offsetting $0.10 to $0.15 for Edwards is a big move and really impressive. Maybe speak to sort of the undertaking you’re doing to be able to offset that kind of headwind between tariffs and Yenovale dilution?

Scott Ullem: Yeah. Thanks for the question. You know, obviously, we’ve been anticipating the approval of Yenovale and running a bunch of scenarios in the event that we’re successful getting it closed, which we think we will. Our guidance for the year did not anticipate an impact from Yenovale, but we’ve had plans to be able to take action when we got some confirmation and more confidence that we’re gonna get it closed. So we’re ready to go. We do think that spending will step up a bit in the second quarter because it was lower than what we originally had planned and expected in Q1. And that’s really the reason why we ended up with $0.64 a share in EPS in the first quarter. You know, we’re gonna be looking at things like investments that are planning to make that are more discretionary in 2025 that will not impact our sales guidance for this year.

But at this point, we’re not gonna get into a lot more of the detail about where those items are. You know, I mentioned in the prepared remarks that we’re really focusing hard on prioritizing our R&D investments and really focusing on things that can drive top-line organic growth and profitable growth and earnings over the long term. We’re gonna keep doing that. Again, I think we can continue to execute our focus strategy while also doing what we need to do to offset those headwinds that we’re facing now in 2025.

Bernard Zovighian: So just to add on that, you know, Scott, you know, what I said, I would say it we are very pleased about, you know, the way we are starting the year. Strong Q1, you know, sales, you know, slightly better than expected. You know, EPS top end of a range. We are, you know, we have, you know, we have achieved, you know, so many milestones in Q1. You have seen, you know, all of them where we are going to be able to create, you know, new category for us. Think about, you know, a multiyear growth opportunity ahead of us, based on these, you know, new medicines. Then, you know, you know, full-year outlook, confident, 8% to 10%, raising of the TMTT guidance, and being able to offset Yenovale’s dilution and basically the tariff impact. You know, we feel good about the year. We feel good about how we are running the company.

Robbie Marcus: Thank you. Great. Maybe just a quick follow-up. The TMTT guidance range, part of it’s FX, part of it’s underlying. You know, first quarter was good, but still pretty much in line with TheStreet. How are you thinking about the split between FX and underlying and sort of the key drivers of progression in the raised guide through the rest of the year? Thanks a lot.

Scott Ullem: Sure. I’ll just confirm on FX and then pass over to Daveen to talk about just the operational performance and our outlook for the rest of the year. You know, for FX, you know, think about this $100 million benefit that we’re getting through the movement in FX rates, and just spreading that across our businesses, probably about half of the increase in TMTT guidance comes from FX and the other half from operational. Then the balance of that $100 million would be spread across the other businesses. Of course, TAVR would be the biggest place for that to go. Daveen, you wanna talk about the other half of the guidance increase?

Daveen Chopra: On the operational side of things, as you can imagine, we continue to see great momentum on both Pascal as well as Evoque. So both are kind of key drivers both in Q1 and going forward as we just treat more and more patients. From maybe even I’ll give you just a geography component, so it’s good to look at that way as well. We see both coming from both the US and Europe. But, you know, in both these markets, Pascal continues to show its differentiation and Evoque as a new category continues to create treat new patients who don’t have great outcomes. So we see continued growth happening from that side as well.

Robbie Marcus: Appreciate it. Thank you very much.

Operator: Our next question comes from the line of Vijay Kumar with Evercore ISI. Please proceed.

Vijay Kumar: Hey, guys. Thank you for taking my question. Scott, I had a couple of guidance clarifications, if you will. Maybe on the EPS guidance here, you called out the tariff headwinds in Yenovale. Are we expecting to offset, you know, that increment $0.10 to $0.15 of headwinds completely or should we be perhaps looking at the bottom half of the guidance range? Just, you know, maybe walk us through on what the offsets are.

Scott Ullem: Yeah. So it’s a little premature to be more precise about where within that $2.40 to $2.50 we may fall. And the reason is because we haven’t closed Yenovale yet. So part of this depends upon the timing of that close and when we start picking up some of that burn. And part of it depends upon what the integration plan looks like and what we’re actually gonna execute. That’s why we gave a range and that’s why we think that the $2.40 to $2.50 range in EPS can accommodate different scenarios.

Vijay Kumar: Understood. And maybe one on international. Japan was a little light. Maybe talk about trends within Japan.

Bernard Zovighian: Yeah. No. Thanks, Vijay, for the question. So for sure, you know, our results in the quarter and even, you know, the last quarter were, you know, less than expected, a little bit disappointing, you know, for us. But we are very optimistic about Japan. You know, what we have seen is a couple of things happening. Weaker procedure growth environment, and we need to better understand that, you know, what’s happening there. And also some competitive pressure. So, you know, what we are doing is, you know, a couple of things. One is enhancing our capability in the region in Japan to accelerate market growth. One, and better position our technology. You know that when our technology is, you know, very differentiating.

You know, when we bring our technology to patients, evidence demonstrates that we live longer, better quality of life, we avoid, you know, hospitalization, complication, this is the kind of value we bring. We have a good story to tell, you know, and I believe, you know, we are going to have, you know, all of the Japanese, you know, physicians responding very well, you know, to this. We are also enhancing, you know, capability in Japan to address the situation. So overall, you know, long term in Japan, see a big potential. Aging population, there is a lot of AS patients, mitral patients, tricuspid patients. So clearly an opportunity for us, an opportunity to change, you know, patient care there.

Vijay Kumar: Understood. Thank you.

Operator: Our next question comes from the line of Matt Taylor with Jefferies. Please proceed.

Matt Taylor: Hi. Thanks for taking the question. I did want to follow-up on TMTT. I heard your comments and guess I just wanted to confirm that none of the guidance range was really around M3. And also just wanted to think about how to maybe compare and contrast the launch of the mitral replacement versus what you’ve seen with Evoque and tricuspid? Should we expect it to be similar and can you talk about when the European launch will start to contribute and what to expect from the US?

Daveen Chopra: Yeah. Sure. This is Daveen, Matt. I can take that question. So first, the first part of your question, yes, you’re correct that we had built in M3 into our original range for the year already. And the change in guidance did not have to do with the specific CE Mark or the timing of CE Mark. We’d already kind of built it in. And as we look at this kind of therapy, we’re, you know, we’re beginning with a very controlled launch that’s emphasis on this really high touch model that we have of supporting physicians and patients to ensure the highest quality outcome. The indication though of mitral replacement in Europe is different. It is more similar to Evoque in Europe and different than what we see Evoque in the US.

Meaning, as I mentioned, mitral replacement is for patients who are unsuitable for mitral surgery or for TIR. So for that, yeah, we expect a gradual buildup. And in Europe, as you can imagine, we’re drawing on our therapy and our experience and how to create categories. Because each country in Europe is very unique. There are different ways of getting incremental payment and coverage for our therapies, and we’ve gotta work on that one at a time, and that takes time. Additionally, we gotta train physicians, train our own team, and build it up. So we really see SAPIEN M3 in Europe being more of a gradual, long-term, important category of adding new patients with mitral disease to be treated. And, yeah, hopefully, that’s helped.

Matt Taylor: That’s great. And then any maybe you could just finish with the US, how that’ll be different?

Daveen Chopra: Yeah. So in the US, different than Evoque in the US, as you can imagine, mitral replacement, again, the US will also have indication unsuitable for TIR and mitral surgery. So, again, these patients are already in the funnel. They might not be appropriate for surgery or TIR. They don’t have any other option. And now for many of those patients, M3 will be an option. Evoque, as you know, when we launched it, had a different broader indication for people for health status improvement for people with tricuspid disease. So there’s not this layer of first, are you appropriate for TIR or surgery? So with that, we would expect that the US mitral launch in general would be at a slightly slower rate probably that would be at a slower rate than we think what we saw with Evoque.

But either way, we really see that the great news about this is that this technology, replacement is really complementing TIR and adding patients to allow us for that kind of multiple years of growth as we add more patients with this new treatment.

Matt Taylor: Great. Thank you so much.

Operator: Thank you. Our next question comes from the line of Joanne Wuensch with Citibank. Please proceed.

Joanne Wuensch: Good afternoon, and thanks for taking the question. I just want to hit pause on the early TAVR label expansion and NCD because I think there’s a couple of different things that are happening here. And correct me if I’m wrong. One is the label expansion, the second one is the NCD. The NCD could expand the number of it could expand maybe something else. And I’ve also heard from some physicians maybe an expectation that it might eliminate the need for a cardiac surgery team in the OR. So clarify what you think may happen and then how long after all of that starts to layer on do you think, you know, procedures start to ramp? Thank you.

Bernard Zovighian: Yeah. Thanks, Joanne. You know, I think there’s a multitude of developments here. First thing is the label expansion, you know, which obviously is under FDA’s control. And again, we expect that to happen in Q2. So that’s kind of step one. The national coverage decision, you know, that’s under the purview of CMS and, you know, they’ll decide, you know, when they want to reopen that and when they want to reevaluate it. And, you know, given the safety of TAVR that’s been demonstrated and the national registry that we have that really confirms the outstanding results across all of the centers that we’ve opened. We do expect there to be an expansion in the number of centers. How many will that be? You know, that’s gonna be up to how they write the policy and how that plays out.

And, you know, we’ll see how they decide to streamline the team and, you know, try to make the healthcare system more efficient. The third big element is guidelines, which fall under the society purview. And, you know, how do they take this data? How do they update the guidelines? So that patients with, you know, severe aortic stenosis but having yet pursued the symptoms, how do we make sure that they move through the healthcare system properly screened and they’re treated in accordance with what the data suggests. And I think, you know, we’re still in that education process with a lot of folks. You know, there’s sometimes people think that asymptomatic patients are automatically younger patients, but what we saw in the trial is I think the average age was 76, where for our lowest trial, it was 73.

So these aren’t necessarily younger patients. You know, we’re not necessarily treating them at a much younger age. So I think these things are all important things that we just need to keep reiterating. And again, once we have the approval, it really takes the shackles off of being able to really advance our education platform and advance our ability to promote this. But until we get the FDA approval, we’re just, you know, we’re just kind of at a standstill beyond what the physicians themselves, the investigators, and people do at the big medical meetings.

Joanne Wuensch: Very helpful. Thank you.

Operator: Thank you. Our next question comes from the line of Pito Chickering with Deutsche Bank. Please proceed.

Pito Chickering: Hey, guys. I was following up on these NCD questions. You know, our calls with the physicians that, you know, CMS is actually in sort of final discussions with the societies and health system about relaxing this NCD to, you know, to be certified to IRS centers and that this change could actually be coming, yeah, in May or in June. Is this timing something that you guys have heard as well?

Bernard Zovighian: There’s no predetermined timing. You know, it opens whenever CMS decides that they want to open it, and that is completely within their purview. And no one frankly has any influence over that. It’s completely within their realm of control. So anybody that provides specific timing, they’re simply speculating as to when they think, you know, when they think that that could happen. So I don’t have any insights beyond what I’ve already stated, and it’s gonna be up to them. Again, we do expect that, you know, a new policy, I think we have plenty of experience with the technology now. I do think the new policy will reflect the safety that we’ve demonstrated. And I do expect that at some point the policy is going to reopen.

And, you know, I think one of the catalysts in front of CMS is going to be the asymptomatic approval. And one of the things we’ve seen historically, you know, when we first got approval for SAPIEN, it was under local coverage and it did lead to some inconsistencies with how things were done. And that really drove CMS to open the NCD because they wanted to make sure that patients across all of their constituents could be treated under a national policy. So I expect that to happen again. When exactly is gonna be completely up to them. But when they do, then we get to engage them. We get to start that process and, you know, hopefully, end up with a policy that, you know, is going to allow more patients access to life-saving therapy.

Pito Chickering: Great. And then a follow-up here. Can you guys give us an update on how the demand for training for Evoque is going? And any color on how many sites have been trained and or in the process to be trained? Thanks so much.

Daveen Chopra: Oh, sure. This is Daveen again. Yeah. So first, in terms of Evoque sites, as you can imagine, I think I mentioned before, you know, we started originally at those first fifty or sixty clinical trial sites. And then from them and continuing to invest in new sites that are working with sites that are investing in tricuspid disease. So that number is a growing number. We continuously are booking our trial sites out for several months in advance. So right now, if you’re interested in a trial site, it’s at least a couple of months away. So it’s been consistently like that where the demand from physicians to get trained has been always a little bit greater than maybe our ability to open sites just in the ramp. And this really, as you know, has to do with the value proposition where people are seeing how the elimination of TR with Evoque is really changing patients’ lives and as a result, both physicians and patients are asking for the technology.

And so in general, though, as you can imagine, as Larry just mentioned there, what 850 TAVR centers or so. I mean, it’s a very big number. And our goal is some number of those would be great for tricuspid treatment including Evoque, and we continue each year just to keep opening and training new centers for many years to come. Just like TAVR did over the course of many years.

Pito Chickering: Great. Thanks so much.

Operator: Thank you. Our next question comes from the line of Chris Pasquale with Nephron. Please proceed.

Chris Pasquale: Thanks. The 2.6% surgical growth this quarter was the slowest we’ve seen from that business in a while. I know selling days had a bit of an impact. Can you just talk about your confidence in being able to sustain mid-single-digit growth in that segment, especially now that the Resilia platforms have really become dominant in many of your big markets, you don’t have as much of a tailwind from mix?

Scott Ullem: Yeah, Chris. Thanks for the question there. In Q1, we did have some challenging comps when we considered it compared to the prior year when the business was growing in the high single-digit range. I think looking forward in 2025, as you heard from Bernard, you know, we’re launching Mitris in China. We’ve got some other potential tailwinds later on this year with the approval of Connect in Europe. And so we are remaining confident in our current guidance in the mid-single-digit range for 2025.

Chris Pasquale: Great. That’s helpful. And I know that this may be a bit difficult to answer given that the deal isn’t closed yet, but we saw some updated data from the AlignAR trial at ACC. Continues to look solid. We’re about eighteen months out now from the original data presentation. Just any help you can give us in terms of what we should expect for a regulatory pathway and approval timing for that product.

Bernard Zovighian: Yeah. Actually, we don’t have anything that we can talk about on that. You know, we’re sort of pencils down until the deal closes. So we don’t have any direct knowledge. You know, we’re not in conversation with them. Until the deal closes, you know, we’re sort of on the outside looking in. So I don’t have any more information than what you saw presented at ACC.

Chris Pasquale: Alright. Thanks.

Operator: Thank you. Our next question comes from the line of Patrick Wood with Morgan Stanley. Please proceed.

Patrick Wood: Beautiful. Thank you so much, guys. I guess maybe on Pascal, doing pretty well. You know, where are we at in terms of, you know, account sort of breadth versus depth? I’m thinking, like, is the utilization sort of where you would like it to be? I’m trying to work out how wide you are versus how deep within individual accounts.

Daveen Chopra: Yeah. Sure. If you think about Pascal overall, we continue to see that this product has feature differentiation that we believe is leading to really predictable and positive outcomes for patients. And you see that in accounts who currently have access to Pascal that as they use Pascal more and more, see those great patient outcomes and then they want to use it more. And then as you can imagine, they then tell their friends through different types of programs that congresses that sites who today who don’t use Pascal are interested in trying to use it. So that’s how we see it spreading in both increased depth in certain centers as well as opening new centers. In terms of the number of centers, maybe specific, I’ll just speak to the US.

Again, I’ll maybe use the generic counter. If there are 850 TAVR centers, give or take, in the US or so, our goal is to grow into many of these as many of these that make sense. But today, we’re definitely in less than fewer than 50% of them. So there’s still a lot of opportunity for growth. Both in new accounts as well as increasing penetration and seeing those great patient outcomes in the sites that currently use Pascal.

Patrick Wood: Excellent. That’s helpful. And then very quickly, there’s been a lot of sort of shuffle around with the FDA overall and people fired, rehired, that side of things. Is there any expectation from you guys that approval timelines long term could be affected or anything like that, or is this just short-term noise that we can ignore?

Bernard Zovighian: Yeah. Obviously, you know, the situation is a fluid one, and we are all, you know, watching. But so far, we don’t see any change, you know, with the FDA approval timeline, response to any submission, you know, all of that. So, you know, we feel like, you know, the people at the FDA are very professional. They are very committed to the space. And we don’t see any impact. And we don’t believe we will see an impact. But, obviously, it is a fluid situation that we need to monitor.

Patrick Wood: Awesome. Thanks, Bernard.

Operator: Thank you. At this time, this concludes the allotted question and answer session time. I would like to pass the call back over to management for any closing remarks.

Bernard Zovighian: Yes. So, you know, thank you everyone for your interest. You know, so beyond the strong start of the year, you know, I’m very excited about, you know, what we were able to achieve, you know, in Q1 with this, you know, very strong, you know, catalyst. If you step back and you look at them, you know, we are on track to get an early TAVR indication approval in Q2. We had an NCD for Evoque. SAPIEN M3 CE mark which, you know, basically represents the start of a new category for us. Resilia, ATA, amazing outcome. So all of that, you know, together give us, you know, confidence in what we told you in December at our investor conference. We believe we are very well positioned to transform care for the many structural heart patients.

And we are continuing to target, you know, total company sales growth of 10% annually on average. So, again, very pleased about the year, the numbers, all of the catalysts. I think all of our people, 16,000 employees are doing amazing work and I want to thank them for that. Thanks for your interest in the company. And if you need any questions, do not hesitate to call Sid, Mark, Scott, or myself. Have a great rest of your day. Thank you.

Operator: That concludes today’s teleconference. You may disconnect your lines at this time. Thank you for your participation.